A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose
of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged
unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy